Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study
Abstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasiv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-025-02058-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102500865081344 |
|---|---|
| author | Karen Van Baelen Ha-Linh Nguyen François Richard Gitte Zels Maria Margarete Karsten Guilherme Nader-Marta Peter Vermeulen Luc Dirix Adam David Dordevic Evandro de Azambuja Denis Larsimont Marion Maetens Elia Biganzoli Hans Wildiers Ann Smeets Ines Nevelsteen Patrick Neven Giuseppe Floris Christine Desmedt |
| author_facet | Karen Van Baelen Ha-Linh Nguyen François Richard Gitte Zels Maria Margarete Karsten Guilherme Nader-Marta Peter Vermeulen Luc Dirix Adam David Dordevic Evandro de Azambuja Denis Larsimont Marion Maetens Elia Biganzoli Hans Wildiers Ann Smeets Ines Nevelsteen Patrick Neven Giuseppe Floris Christine Desmedt |
| author_sort | Karen Van Baelen |
| collection | DOAJ |
| description | Abstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasive lobular carcinoma (ILC). Here, we aimed at analyzing the association of HER2-low with clinicopathological features and survival outcomes in patients with early-stage pure ILC. Methods A multicentric retrospective cohort of patients diagnosed with stage I-III estrogen receptor positive (ER+) HER2 negative (HER2-) ILC between 01/01/2000 and 12/31/2020 was assembled. HER2- disease was categorized further by immunohistochemical (IHC) score into HER2 0, HER2 1+ and HER2 2+ following time appropriate ASCO/CAP guidelines from 2007 onward and by local guidelines prior to 2007. The association of HER2-low (HER2 1+ and 2+) with clinicopathological variables was assessed using multinomial logistic regression. Survival analyses were performed to evaluate the association of HER2-low with disease-free (DFS), distant recurrence-free (DRFS) and overall survival (OS). Results The data of 2098 patients with ER+ HER2- ILC was collected of which 1103 (52.6%) had a HER2-low tumor. Of these 716 (34.1%) had an IHC score of HER2 1+ and 387 (18.4%) of HER2 2+. In multivariable analysis, both tumor size of ≥ 2cm (OR: 1.37; 95%CI 1.01 – 1.87; p-value 0.042) and multifocality (OR: 1.55; 95%CI 1.11 – 2.15; p-value 0.009) were associated with HER2-low. HER2-low was associated with worse DFS (HR: 1.32; 95%CI 1.06 − 1.66; p-value 0.015) and OS (HR: 1.42; 95%CI 1.12 − 1.81; p-value 0.004) as compared to HER2 0. No association of HER2-low with DRFS was observed. Conclusions HER2-low is present in more than half of the patients with early ER+ HER2- pure ILCs and is associated with larger tumor size and multifocality. HER2-low is associated with a worse DFS and OS as compared to HER2 0. |
| format | Article |
| id | doaj-art-52831d5e7c6d49c8aa5614bade242be7 |
| institution | DOAJ |
| issn | 1465-542X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Breast Cancer Research |
| spelling | doaj-art-52831d5e7c6d49c8aa5614bade242be72025-08-20T02:39:44ZengBMCBreast Cancer Research1465-542X2025-06-0127111310.1186/s13058-025-02058-xAssociation of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen0Ha-Linh Nguyen1François Richard2Gitte Zels3Maria Margarete Karsten4Guilherme Nader-Marta5Peter Vermeulen6Luc Dirix7Adam David Dordevic8Evandro de Azambuja9Denis Larsimont10Marion Maetens11Elia Biganzoli12Hans Wildiers13Ann Smeets14Ines Nevelsteen15Patrick Neven16Giuseppe Floris17Christine Desmedt18Department of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenDepartment of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenDepartment of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenDepartment of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenDepartment of Gynecology and Breast Center, Charité Universitätsmedizin BerlinInstitut Jules Bordet, l’Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B)Department of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenTranslational Cancer Research Unit, Oncology Centre AntwerpDepartment of Gynecology and Breast Center, Charité Universitätsmedizin BerlinInstitut Jules Bordet, l’Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B)Institut Jules Bordet, l’Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B)Department of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenDepartment of Clinical Sciences and Community Health & DSRC, Unit of Medical Statistics, Biometry and Epidemiology “Giulio A. Maccacaro”, University of MilanDepartment of General Medical Oncology, University Hospitals LeuvenDepartment of Surgical Oncology, University Hospitals LeuvenDepartment of Surgical Oncology, University Hospitals LeuvenDepartment of Gynecological Oncology, University Hospitals LeuvenDepartment of Pathology, University Hospitals LeuvenDepartment of Oncology, Laboratory for Translational Breast Cancer Research (LTBCR), KU LeuvenAbstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasive lobular carcinoma (ILC). Here, we aimed at analyzing the association of HER2-low with clinicopathological features and survival outcomes in patients with early-stage pure ILC. Methods A multicentric retrospective cohort of patients diagnosed with stage I-III estrogen receptor positive (ER+) HER2 negative (HER2-) ILC between 01/01/2000 and 12/31/2020 was assembled. HER2- disease was categorized further by immunohistochemical (IHC) score into HER2 0, HER2 1+ and HER2 2+ following time appropriate ASCO/CAP guidelines from 2007 onward and by local guidelines prior to 2007. The association of HER2-low (HER2 1+ and 2+) with clinicopathological variables was assessed using multinomial logistic regression. Survival analyses were performed to evaluate the association of HER2-low with disease-free (DFS), distant recurrence-free (DRFS) and overall survival (OS). Results The data of 2098 patients with ER+ HER2- ILC was collected of which 1103 (52.6%) had a HER2-low tumor. Of these 716 (34.1%) had an IHC score of HER2 1+ and 387 (18.4%) of HER2 2+. In multivariable analysis, both tumor size of ≥ 2cm (OR: 1.37; 95%CI 1.01 – 1.87; p-value 0.042) and multifocality (OR: 1.55; 95%CI 1.11 – 2.15; p-value 0.009) were associated with HER2-low. HER2-low was associated with worse DFS (HR: 1.32; 95%CI 1.06 − 1.66; p-value 0.015) and OS (HR: 1.42; 95%CI 1.12 − 1.81; p-value 0.004) as compared to HER2 0. No association of HER2-low with DRFS was observed. Conclusions HER2-low is present in more than half of the patients with early ER+ HER2- pure ILCs and is associated with larger tumor size and multifocality. HER2-low is associated with a worse DFS and OS as compared to HER2 0.https://doi.org/10.1186/s13058-025-02058-xInvasive lobular carcinomaHER2-lowClinicopathological featuresSurvival |
| spellingShingle | Karen Van Baelen Ha-Linh Nguyen François Richard Gitte Zels Maria Margarete Karsten Guilherme Nader-Marta Peter Vermeulen Luc Dirix Adam David Dordevic Evandro de Azambuja Denis Larsimont Marion Maetens Elia Biganzoli Hans Wildiers Ann Smeets Ines Nevelsteen Patrick Neven Giuseppe Floris Christine Desmedt Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study Breast Cancer Research Invasive lobular carcinoma HER2-low Clinicopathological features Survival |
| title | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study |
| title_full | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study |
| title_fullStr | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study |
| title_full_unstemmed | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study |
| title_short | Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study |
| title_sort | association of her2 low with clinicopathological features in patients with early invasive lobular breast cancer an international multicentric study |
| topic | Invasive lobular carcinoma HER2-low Clinicopathological features Survival |
| url | https://doi.org/10.1186/s13058-025-02058-x |
| work_keys_str_mv | AT karenvanbaelen associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT halinhnguyen associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT francoisrichard associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT gittezels associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT mariamargaretekarsten associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT guilhermenadermarta associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT petervermeulen associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT lucdirix associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT adamdaviddordevic associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT evandrodeazambuja associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT denislarsimont associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT marionmaetens associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT eliabiganzoli associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT hanswildiers associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT annsmeets associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT inesnevelsteen associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT patrickneven associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT giuseppefloris associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy AT christinedesmedt associationofher2lowwithclinicopathologicalfeaturesinpatientswithearlyinvasivelobularbreastcanceraninternationalmulticentricstudy |